Related Experiment Video
Updated: Feb 28, 2026
Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs
Published on: July 23, 2016
Ranibizumab versus dexamethasone implant for central retinal vein occlusion: the RANIDEX study
Irini Chatziralli1,2, George Theodossiadis3, Stamatina A Kabanarou4
12nd Department of Ophthalmology, "Attikon" Hospital, National and Kapodistrian University of Athens, Athens, Greece. eirchat@yahoo.gr.
Purpose:
To compare intravitreal ranibizumab and dexamethasone implant in patients with macular edema (ME) secondary to central retinal vein occlusion (CRVO).
Methods:
Participants were 42 treatment naive patients with ME due to CRVO, who received either intravitreal 0.5 mg ranibizumab (n = 25) or intravitreal 0.7 mg dexamethasone implant (n = 17). The main outcomes included the mean change in best corrected visual acuity (BCVA) and central subfield thickness (CST) at month 12 compared to baseline in the two groups.
Results:
At month 12, there was no statistically significant difference in BCVA and CST change between the two groups. However, there was recurrence in ME at month 5 in the dexamethasone group.
Conclusions:
Both ranibizumab and dexamethasone implant were found to be safe and effective at the 12-month follow-up in patients with ME secondary to CRVO. Since there was a recurrence in ME at month 5 in the dexamethasone group, we suggested that intravitreal injection of dexamethasone implant should be potentially administered sooner than 6 months.
